Meta-analysis data from three clinical trials (CheckMate 057, POPLAR and KEYNOTE 010) proved that PD-1/PD-L1 ICIs did not prolong OS (HR=1.05, 95% CI: 0.70-1.55, P=0.81) in EGFR-mutant NSCLC patients (35) compared with docetaxel. This evidence concerns the gene EGFR and non-small cell lung carcinoma.